Oxford BioDynamics PLC on Tuesday announced a new partnership with The London Clinic.
The partnership will see the Oxford, England-based biotech company provide the UK s largest independent.
The following stocks are the leading risers and fallers on AIM in London on Tuesday.
AIM - WINNERS
Empire Metals Ltd, up 45% at 2.69 pence, 12-month range 0.75p-2.85p. says its. | May 30, 2023
Oxford BioDynamics PLC said on Tuesday that the company will need to generate increased revenue or find additional funding in the remainder of the year, as its half-year loss widened.
Shares in the. | June 7, 2023
IN BRIEF: Oxford BioDynamics Annual Revenue Hurt By Covid-19 Pandemic
Thu, 28th Jan 2021 20:25
Oxford BioDynamics PLC - biotechnology firm focused on discovery and development of epigenetic biomarkers - Says 2020 was a year of transition and development with company readying for near-term commercialisation of its 3D genomics technology platform, EpiSwitch. Says R&D project revenues were affected by the Covid-19 pandemic. For year ended September 30, posts revenue of GBP456,000 down from GBP907,000 as pretax loss widens to GBP4.9 million from GBP3.4 million.
Chief Executive Officer Jon Burrows says: Despite the tribulations of the pandemic, OBD has made significant strategic and organizational progress over the year. We enter 2021 with an expanded strategic focus, team, and infrastructure to drive near-term commercialization of the EpiSwitch technology, via multiple commercial pathways, beginning with our COVID-19 severity test. The next anticipated launch, later in 2021, will be